BTC Health (BTC) Stock Price, News & Analysis

Company Overview

BTC Health Limited is a Pooled Development Fund managed by LHC Capital Partners Pty Ltd specializing in seed/startup, early venture, mid venture, late venture, emerging growth and growth capital investments. It makes investments in the healthcare and biotechnology sector with a focus on post-genomics, stem cell biology, convergence, silicon biology, and nanomedicine. Within post-genomics, it invests in functional genomics, transcriptomics, proteomics, structural genomics, glycomics, and pharmacogenomics. In the stem cell biology sector, the fund focuses on stem cell therapies. Within convergent technologies, it invests in biomaterials, bionics, biosensors, tissue engineering, microfluidics, and moletronics. In the silicon biology sector, the fund focuses on structure-based drug design, virtual screening, computational library design, and in silico ADME/tox. It invests in companies based in Australia New Zealand. The fund invests in both listed and unlisted companies.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: A$19.77 million
• P/E Ratio: 18.74
• Dividend Yield: 28.00%
• Price Target: N/A
• Consensus Rating: N/A

BTC Stock Analysis - Frequently Asked Questions

What other stocks do shareholders of BTC Health own?

Based on aggregate information from My MarketBeat watchlists, some other companies that BTC Health investors own include Global X Cloud Computing ETF (CLOU), Mesa Air Group (MESA), Meta Platforms (META), Walmart (WMT), Invesco High Yield Equity Dividend Achievers ETF (PEY), Sorrento Therapeutics (SRNE) and Tesla (TSLA).

Industry, Sector and Symbol

• Stock Exchange: ASX
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: ASX:BTC
• CIK: N/A
• Web: www.biotechcapital.com.au
• Phone: 61 4 1305 6328
• Fax: N/A
• Employees: 1
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: 18.74
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: A$1.06 million
• Net Margins: 6,450.41%
• Pretax Margin: N/A
• Return on Equity: 20.37%
• Return on Assets: -10.19%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.98
• Quick Ratio: 14.12

Sales & Book Value

• Annual Sales: A$1.98 million
• Price / Sales: 0.00
• Cash Flow: N/A
• Price / Cash Flow: 5.36
• Book Value: A$0.02 per share
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: 324,120,000
• Free Float: N/A
• Market Cap: A$19.77 million
• Optionable: Not Optionable
• Beta: 0.26